30 / 80
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 3, May/June 2017
164
AFRICA
ghrelin in blood samples.
Clin Chem
2004;
50
: 1077–1080. PMID:
15161728.
24. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma
T,
et al
. Ghrelin, a novel growth hormone-releasing acylated peptide, is
synthesized in a distinct endocrine cell type in the gastrointestinal tracts
of rats and humans.
Endocrinology
2000;
141
: 4255–4261.
25. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough
P,
et al
. The tissue distribution of the mRNA of ghrelin and subtypes
of its receptor, GHS-R, in humans.
J Clin Endocrinol Metab
2002;
87
:
2988. PMID: 12050285.
26. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum
CI,
et al
. A receptor in pituitary and hypothalamus that functions in
growth hormone release.
Science
1996;
273
: 974–977. PMID: 8688086.
27. McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips
MS,
et al
. Molecular analysis of rat pituitary and hypothalamic growth
hormone secretagogue receptors.
Mol Endocrinol
1997;
11
: 415–423.
PMID: 9092793.
28. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and desacyl
ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue.
Biochem Biophys Res Commun
2000;
279
: 909–913. PMID: 11162448.
29. Zhang W, Zhao L, Lin TR, Chai B, Fan Y, Gantz I,
et al
. Inhibition
of adipogenesis by ghrelin.
Mol Biol Cell
2004;
15
: 2484–2491. PMID:
15034137.
30. Gourcerol G, Coskun T, Craft LS, Mayer JP, Heiman ML, Wang
L,
et al
. Preproghrelin-derived peptide, obestatin, fails to influence
food intake in lean or obese rodents.
Obesity
(Silver Spring) 2007;
15
:
2643–2652. PMID: 18070755.
31. Tremblay F, Perreault M, Klaman LD, Tobin JF, Smith E, Gimeno RE.
Normal food intake and body weight in mice lacking the G protein-
coupled receptor GPR39.
Endocrinology
2007;
148
: 501–506. PMID:
17095592.
32. Gröschl M, Topf HG, Bohlender J, Zenk J, Klussmann S, Dötsch J,
et
al
. Identification of ghrelin in human saliva: production bythe salivary
glands and potential role in proliferation of oral keratinocytes.
Clin
Chem
2005;
51
: 997–1006. PMID: 15790755.
33. Laurila M, Santaniemi M, Kesäniemi YA, Ukkola O. High plasma ghre-
lin protects from coronary heart disease and Leu72Leu polymorphism
of ghrelin gene from cancer in healthy adults during the 19 years follow-
up study.
Peptides
2014;
61
: 122–129. PMID: 25257375.
34. Sax B, Merkely B, Túri K, Nagy A, Ahres A, Hartyánszky I,
et al
.
Characterization of pericardial and plasma ghrelin levels in patients
with ischemic and non-ischemic heart disease.
Regul Pept
2013;
186
:
131–136.
35. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W,
et al
. Chronic administration of ghrelin improves left ventricular func-
tion and attenuates development of cardiac cachexia in rats with heart
failure.
Circulation
2001;
104
: 1430–1435. PMID: 11560861.
36. Nagaya N, Kangawa K. Ghrelin, a novel growth hormone-releasing
peptide, in the treatment of chronic heart failure.
Regul Pept
2003;
114
:
71–77. PMID: 12832093.
37. Xu X, Jhun BS, Ha CH, Jin ZG. Molecular mechanisms of ghrelin-
mediated endothelial nitric oxide synthase activation.
Endocrinology
2008;
149
: 4183–4192. PMID: 18450953.
38. Katugampola SD, Maguire JJ, Kuc RE, Wiley KE, Davenport AP.
Discovery of recently adopted orphan receptors for apelin, urotensin
II, and ghrelin identified using novel radioligands and functional role
in the human cardiovascular system.
Can J Physiol Pharmacol
2002;
80
:
369–374. PMID: 12056541.
39. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa
K. Vasodilatory effect of ghrelin, an endogenous peptide from the
stomach.
J Cardiovasc Pharmacol
2002; 39: 779–783. PMID: 12021570.
40. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M.
Ghrelin acts at the nucleus of the solitary tract to decrease arterial pres-
sure in rats.
Hypertension
2004;
43
: 977–982. PMID: 14993197.
41. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL,
et al
. Weight gain decreases elevated plasma ghrelin concentrations of
patients with anorexia nervosa.
Eur J Endocrinol
2001;
145
: 669–673.
PMID: 11720888.
42. Rigamonti AE, Pincelli AI, Corrà B, Viarengo R, Bonomo SM,
Galimberti D,
et al
. Plasma ghrelin concentrations in elderly subjects:
comparison with anorexic and obese patients.
J Endocrinol
2002;
175
:
1–5. PMID: 12379512.
43. Iglesias MJ, Salgado A, Piñeiro R, Rodiño BK, Otero MF, Grigorian
L,
et al
. Lack of effect of the ghrelin gene-derived peptide obestatin on
cardiomyocyte viability and metabolism.
J Endocrinol Invest
2007;
30
:
470–476. PMID: 17646721.
44. Boulot-Tolle M, Chadefaux B, Kamoun P. Salivary homocyst(e)ine
concentrations.
Clin Chem
1992;
38
: 1504–1505. PMID: 1643725.
45. Nygard O, Vollset SE, Refsum H, Ueland PM, Vollset SE. Total plasma
homocysteine and cardiovascular risk profile. The Hordaland homo-
cysteine study.
J Am Med Assoc
1998;
274
: 1526–1533. PMID: 7474221.
46. Brattström L. Vitamins as homocysteine-lowering agents.
J Nutr
1996;
126
: 1276–1280. PMID: 8642470.
47. Pasterkamp G, Algra A, Grobbee DE, Banga JD, van der Graaf Y.
Homocysteine and the stage of atherosclerotic disease: A study in
patients suffering from clinically silent and clinically manifest athero-
sclerotic disease.
Eur J Clin Invest
2002;
32
: 309–315. PMID: 12027869.
48. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen
DW. Homocysteine induces expression and secretion of monocyte
chemo attractant protein-1 and interleukin-8 in human aortic endothe-
lial cells: Implication for vascular disease.
Circulation
2001;
103
: 2717–
2723. PMID: 11390343.
49. Wang G, Siow YL. Homocysteine induces monocyte chemoattractant
protein-1 expression by activating NF-kappa B in THP-1 macrophages.
Am J Physiol Heart Circ Physiol
2001;
280
: 2840–2847. PMID:
11356643.
50. Zhong-qun Y, Goran KH. Innate immunity, macrophage activation
and atherosclerosis.
Immunol Rev
2007;
219
: 187–203. PMID: 17850490.
51. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and
coronary artery disease.
Med Sci Monit
2002;
8
: 5–12. PMID: 11782689.
52. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset
SE. Plasma homocysteine levels and mortality in patients with coronary
artery disease.
N Eng J Med
1997;
337
: 230–236. PMID: 9227928.
53. Bhargava S, Parakh R, Manocha A, Ali A, Srivastava LM. Prevalence
of hyperhomocysteinemia in vascular disease: comparative study of
thrombotic venous disease vis-à-vis occlusive arterial disease.
Vascular
2007;
15
: 149–153. PMID: 17573020.
54. Hedayati N, Annambhotla S, Jiang J, Wang X, Chai H, Lin PH,
et
al
. Growth hormone-releasing peptide ghrelin inhibits homocysteine-
induced endothelial dysfunction in porcine coronary arteries and human
endothelial cells.
J Vasc Surg
2009;
49
: 199–207. PMID: 19028051.
55. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite
the good, the bad, and ugly.
Am J Physiol
1996;
271
: 1424–1437. PMID:
8944624.
56. Meyer M, Schreck R, Baeuerle PA. H
2
O
2
and antioxidants have opposite
effects on activation of NFkappa B and AP-1 in intact cells AP-1 as
secondary antioxidant-responsive factor.
EMBO J
1993; 12: 2005–2015.
PMID: 8491191.
57. Shibanuma M, Kuroki T, Nose K. Superoxide as a signal for increase
in intracellular pH.
J Cell Physiol
1988;
136
: 379–383. PMID: 2842350.